argenx SE operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares argenx SE with three other
companies in this sector in UNITED STATES :
Adaptive Biotechnologies Corp
sales of $85.07 million
of which 100%
was Biotechnology & Medical Research),
Zyla Life Sciences
of which 52%
was Partnered Discovery).
Sales increased substantially in 2019:
argenx SE reported sales of $78.00 million
December of 2019.
increase of 208.2%
versus 2018, when the company's sales were $25.31 million.
Sales of Research and Development Service Fees (F saw an increase
that was more than double the company's growth rate: sales were up
1,203.8% in 2019, from
$1.66 million to $21.62 million.